LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and between MEI PHARMA, INC., and KYOWA KIRIN CO., LTD. EFFECTIVE DATE: APRIL 10, 2020Development and Commercialization Agreement • September 9th, 2020 • MEI Pharma, Inc. • Pharmaceutical preparations • New York
This License, Development and Commercialization Agreement (this “Agreement”), dated as of April 10, 2020 (the “Effective Date”), is made by and between MEI Pharma, Inc., a Delaware corporation having an office at 3611 Valley Centre Drive STE 500, San Diego, CA 92130 (“MEI”), and Kyowa Kirin Co., Ltd. (formerly known as Kyowa Hakko Kirin Co., Ltd.), a Japanese corporation having an office at 1-9-2 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan (“KKC”). MEI and KKC are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
